1 - 3 June, 2027
Congress CenterBasel Switzerland Davide CortiSVP, Antibody Research at Vir BiotechnologySpeaker
Profile
Dr. Davide Corti is Senior Vice President of Antibody Research at Vir Biotechnology and a leading expert in monoclonal antibody discovery. With a Ph.D. from the University of Bern and postdoctoral training under Antonio Lanzavecchia, he co-founded Humabs BioMed, later acquired by Vir. Dr. Corti developed innovative methods to isolate antibodies, resulting in FDA-approved treatments for Ebola (Ebanga) and COVID-19 (Xevudy), as well as promising candidates for hepatitis D and influenza. He has published 167 research papers, holds over 100 patents, and is consistently recognized among the world's top-cited scientists and industry leaders.
Agenda Sessions
PRO-XTEN™ Masked T Cell Engagers: Protease-activated TCEs for Tumor-specific Targeting
, 16:45View Session